If IFX and ADA were compared, the conclusions would be that both effectively suppress uveitis, that IFX has a fast-acting and potent anti-inflammatory effect equivalent to that of IV pulse methylprednisolone but should be combined with an antimetabolite due to its high immunogenicity (autoantibody formation, loss of effect, infusion reaction), whereas ADA is more effective at inducing sustained remission and is safer and more appropriate as monotherapy due to its lower risk of immunogenicity. The gene discussed is ADA; the disease is uveitis.